Proparacaine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Proparacaine: From Ocular Surface Anesthesia to Cauda Equina Syndrome
One-Sentence Summary
Proparacaine is a topical ocular local anesthetic, registered in Singapore as a sterile ophthalmic solution. The TxGNN model predicts it may be effective for cauda equina syndrome, but this is a computational prediction only, with no clinical trials and no publications supporting this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data (ophthalmic topical anaesthetic) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 96.90% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, proparacaine is a topical ocular local anaesthetic of the same general class as lidocaine, and local anaesthetics generally work by blocking voltage-gated sodium channels.
In theory, sodium channel blockade could relate to neuropathic or radicular pain. However, cauda equina syndrome is a compressive surgical emergency, and a topical eye anaesthetic has no plausible disease-modifying role. The high score reflects network-based computational prediction rather than biological or clinical support. The prediction should be treated with considerable caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for cauda equina syndrome.
For context, the other predicted indications also have very little support:
- Allergic asthma (rank 2): the only retrieved article (28449552, 2017, Clin Exp Otorhinolaryngol) is a preclinical mouse study of proparacaine in allergic rhinitis. It is a different disease and an animal model, so it is indirect evidence.
- Hypotensive disorder (rank 4): the retrieved articles are Cochrane reviews on non-antiepileptic drugs for trigeminal neuralgia (24297506, 21249658, 16856027). They are off-topic and not relevant evidence for this indication.
- Papillary conjunctivitis (rank 6): the most anatomically plausible candidate, since proparacaine is already used on the ocular surface. It is used for anaesthesia, not for treating inflammation, and no studies support a therapeutic effect.
- The remaining predictions (intrinsic asthma, obsolete neurogenic bladder, pityriasis simplex, asthma-related traits, lichen disease, benign recurrent vertigo type 2) have no trials or literature.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04718P | ALCAINE STERILE OPHTHALMIC SOLUTION 0.5% | Solution | Not listed in the registration data |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): The TxGNN knowledge graph links proparacaine to contraindication-type relationships with heart disease, cardiovascular disease, hyperthyroidism, Graves disease, thyrotoxicosis, uveitis, iris disease, ciliary body disease, panuveitis, eye infectious disease and conjunctivitis. These come from a computational knowledge graph rather than a package insert and should be verified against the official label.
- Repeated ocular use: Topical anaesthetics are associated with corneal toxicity on repeated use, which is a major concern for any chronic ocular indication.
- Cardiovascular effects: Local anaesthetics can have systemic cardiovascular effects at high doses, which could worsen hypotension.
- Drug interactions: No interaction records were found.
Please refer to the package insert for complete warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a computational score alone. There are no clinical trials, and the only related literature is indirect or off-topic. A topical ocular anaesthetic has no credible role in a surgical compressive condition such as cauda equina syndrome. The highest-ranked predictions are also mechanistically implausible, and the route of administration does not match.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are currently missing
- Mechanism of action data from DrugBank
- Approved indication text for the Singapore registration
- Assessment of route compatibility between the ophthalmic formulation and any proposed indication
- Clinical or well-designed preclinical evidence specific to a chosen indication
- If any indication is pursued, a better-fitting candidate such as an ocular-surface condition should be evaluated first, with a corneal safety assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.